2025 Hong Kong Biotech IPOA Tale of Two Halves
2025 Hong Kong Biotech IPO: A Tale of Two Halves 2025 Hong Kong Biotech IPOA Tale of Two Halves From […]
blog
Hong Kong Company
blog
The Rise of Mainland-Incorporated Biotech Companies on the Hong Kong Stock Exchange
The Rise of Mainland-Incorporated Biotech Companies on the Hong Kong Stock Exchange The Rise of Mainland-Incorporated Biotech Companies on the
blog
Beyond the IPOPost-Listing Performance, Follow-on Financing, and the ‘B’ Marker Removal
Beyond the IPO: Post-Listing Performance, Follow-on Financing, and the ‘B’ Marker Removal Beyond the IPOPost-Listing Performance, Follow-on Financing, and the
blog
What It Takes to Go Public in Hong KongThe IPO Preparation Journey for Biotech Companies
What It Takes to Go Public in Hong Kong: The IPO Preparation Journey for Biotech Companies What It Takes to
blog
Corporate Governance in Hong Kong-Listed Biotech Companies
Corporate Governance in Hong Kong-Listed Biotech Companies Corporate Governance in Hong Kong-Listed Biotech Companies Board composition, diversity, and leadership —
blog
The Registrar’s Hidden Power: “Continuing Effect” in Hong Kong Company Law
When you’re conducting due diligence on a Hong Kong company, you might come across something puzzling in the official registry:
blog
Struck Off But Not Gone: The 6-Month Secret Life of Dissolved HK Companies
You’ve just discovered that a Hong Kong company you’ve been dealing with—maybe a supplier, a client, or a debtor—has been
blog
Unfinished Investigations: The Ghost of HK Financial Secretary Inspections
When you’re considering investing in, lending to, or partnering with a Hong Kong company, you likely conduct thorough due diligence.
blog
Resurrecting Dead Deals: How Pre-2014 Hong Kong Acquisition Offers Still Bind You
When investing in or acquiring a company in Hong Kong, due diligence often focuses on the present—current financials, active contracts,
blog
The Silent Shift: Tracking Hong Kong Company Secretaries Under New Rules
When you’re researching a Hong Kong company, what do you look at first?Financials, shareholding, legal disputes—the usual suspects. But there’s